Generic placeholder image

Current Pharmaceutical Design

Author(s): Yuan-Rui Xia, Yan-Mei Mao, Jun-Ping Wang, Qing-Ru Li, Yin-Guang Fan, Hai-Feng Pan* and Dong-Qing Ye*

DOI: 10.2174/1381612826666200826135929

DownloadDownload PDF Flyer Cite As
Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis

Page: [5998 - 6006] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Objective: Due to the inconsistent results of current studies on the association between urinary and blood vascular cell adhesion molecule-1 (VCAM-1) and systemic lupus erythematosus (SLE) disease activity, we conducted this study and analyzed its influencing factors.

Methods: A literature search was conducted in PubMed, EMBASE, Web of Science, and Cochrane Library. Data were extracted from eligible studies to calculate standardized mean differences (SMD) with 95% confidence intervals (CI). Cochrane Q test and I2 statistics were used to examine heterogeneity. The sources of heterogeneity were assessed through sensitivity analysis and subgroup analysis. Publication bias was evaluated by funnel plots and Egger's test.

Results: A total of 15 studies met the inclusion criteria, including 473 active SLE patients and 674 inactive SLE patients. The random effects model was used for data analysis. In both urine and blood samples, VCAM- 1 level in active SLE patients was significantly higher than those in inactive SLE patients (urine: SMD: 0.769; 95% CI: 0.260-1.278; blood: SMD=0.655, 95% CI: 0.084-1.226). No publication bias was found in this study.

Conclusion: Compared with inactive SLE patients, patients with active SLE have higher levels of VCAM-1 in both urine and blood. VCAM-1 may be a potential indicator of SLE disease activity.

Keywords: Systemic lupus erythematosus, vascular cell adhesion molecule-1, disease activity, meta-analysis, urine, blood.

[1]
Zucchi D, Elefante E, Calabresi E, Signorini V, Bortoluzzi A, Tani C. One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol 2019; 37(5): 715-22.
[PMID: 31376267]
[2]
Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393(10188): 2344-58.
[http://dx.doi.org/10.1016/S0140-6736(19)30546-X] [PMID: 31180031]
[3]
Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017; 13(8): 799-814.
[http://dx.doi.org/10.1080/1744666X.2017.1327352] [PMID: 28471259]
[4]
Soliman S, Mohamed FA, Ismail FM, Stanley S, Saxena R, Mohan C. Urine angiostatin and VCAM-1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis. Int J Rheum Dis 2017; 20(11): 1714-27.
[http://dx.doi.org/10.1111/1756-185X.13197] [PMID: 29076253]
[5]
Abd-Elkareem MI, Al Tamimy HM, Khamis OA, Abdellatif SS, Hussein MR. Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin Exp Nephrol 2010; 14(6): 548-57.
[http://dx.doi.org/10.1007/s10157-010-0322-z] [PMID: 20714774]
[6]
Smith EM, Jorgensen AL, Midgley A, et al. International validation of a urinary biomarker panel for identification of active lupus nephritis in children. Pediatr Nephrol 2017; 32(2): 283-95.
[http://dx.doi.org/10.1007/s00467-016-3485-3] [PMID: 27590021]
[7]
Janssen BA, Luqmani RA, Gordon C, et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33(12): 1112-6.
[http://dx.doi.org/10.1093/rheumatology/33.12.1112] [PMID: 7528085]
[8]
Mrowka C, Sieberth HG. Circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in systemic vasculitis: marked differences between Wegener’s granulomatosis and systemic lupus erythematosus. Clin Investig 1994; 72(10): 762-8.
[http://dx.doi.org/10.1007/BF00180543] [PMID: 7532481]
[9]
Mok CC, Soliman S, Ho LY, Mohamed FA, Mohamed FI, Mohan C. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. Arthritis Res Ther 2018; 20(1): 6.
[http://dx.doi.org/10.1186/s13075-017-1498-3] [PMID: 29325582]
[10]
Smith EMD, Lewandowski LB, Jorgensen AL, et al. Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus Cohort. Lupus 2018; 27(14): 2190-9.
[http://dx.doi.org/10.1177/0961203318808376] [PMID: 30348048]
[11]
Robak E, Kulczycka L, Sysa-Jedrzejowska A, Wierzbowska A, Robak T. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 2007; 18(4): 181-7.
[PMID: 17964973]
[12]
Mahayidin H, Yahya NK, Wan Ghazali WS, Mohd Ismail A, Wan Ab Hamid WZ. Evaluation of endothelial cell adhesion molecules and anti-C1q antibody in discriminating between active and non-active systemic lupus erythematosus. Malays J Med Sci 2016; 23(3): 22-31.
[PMID: 27418866]
[13]
Parodis I, Gokaraju S, Zickert A, et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford) 2019; 0: 1-13.
[http://dx.doi.org/10.1093/rheumatology/kez528] [PMID: 31722419]
[14]
Elwy MA, Galal ZA, Hasan HE. Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new. East Mediterr Health J 2010; 16(8): 893-900.
[http://dx.doi.org/10.26719/2010.16.8.893] [PMID: 21469572]
[15]
Edelbauer M, Kshirsagar S, Riedl M, et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011; 26(3): 401-10.
[http://dx.doi.org/10.1007/s00467-010-1720-x] [PMID: 21181207]
[16]
Skeoch S, Haque S, Pemberton P, Bruce IN. Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. Lupus 2014; 23(8): 819-24.
[http://dx.doi.org/10.1177/0961203314528061] [PMID: 24647443]
[17]
Kiani AN, Wu T, Fang H, et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol 2012; 39(6): 1231-7.
[http://dx.doi.org/10.3899/jrheum.111470] [PMID: 22505707]
[18]
Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011; 20(12): 1267-74.
[http://dx.doi.org/10.1177/0961203311411597] [PMID: 21813587]
[19]
Hajialilo M, Tayari P, Ghorbanihaghjo A, Khabbazi A, Malek Mahdavi A, Rashtchizadeh N. Relationship between serum vascular cell adhesion molecule-1 and endothelin-1 levels with organ involvement and disease activity in systemic lupus erythematosus patients. Lupus 2018; 27(12): 1918-25.
[http://dx.doi.org/10.1177/0961203318796285] [PMID: 30157717]
[20]
Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. J Rheumatol 2003; 30(10): 2133-9.
[PMID: 14528506]
[21]
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
[http://dx.doi.org/10.1186/1471-2288-5-13] [PMID: 15840177]
[22]
Tedeschi SK, Johnson SR, Boumpas D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res (Hoboken) 2018; 70(4): 571-81.
[http://dx.doi.org/10.1002/acr.23317] [PMID: 28692774]
[23]
Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian rheumatology association recommendations for the assessment and monitoring of systemic lupus erythematosus. J Rheumatol 2018; 45(10): 1426-39.
[http://dx.doi.org/10.3899/jrheum.171459] [PMID: 30173152]
[24]
Fernando MM, Isenberg DA. How to monitor SLE in routine clinical practice. Ann Rheum Dis 2005; 64(4): 524-7.
[http://dx.doi.org/10.1136/ard.2003.015248] [PMID: 15769911]
[25]
Ramirez GA, Canti V, Moiola L, et al. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. Int J Rheum Dis 2019; 22(9): 1752-61.
[http://dx.doi.org/10.1111/1756-185X.13663] [PMID: 31379114]
[26]
Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23(5)(Suppl. 39): S120-32.
[PMID: 16273796]
[27]
Ahearn JM, Liu CC, Kao AH, Manzi S. Biomarkers for systemic lupus erythematosus. Transl Res 2012; 159(4): 326-42.
[http://dx.doi.org/10.1016/j.trsl.2012.01.021] [PMID: 22424435]
[28]
Min DJ, Kim SJ, Park SH, et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 2002; 20(1): 13-8.
[PMID: 11892702]
[29]
Zivković V, Stanković A, Cvetković T, et al. Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus. Srp Arh Celok Lek 2014; 142(7-8): 431-6.
[http://dx.doi.org/10.2298/SARH1408431Z] [PMID: 25233687]
[30]
Ramsey-Goldman R, Li J, Dervieux T, Alexander RV. Cell-bound complement activation products in SLE. Lupus Sci Med 2017; 4(1)e000236
[http://dx.doi.org/10.1136/lupus-2017-000236] [PMID: 29214038]
[31]
Dierckx T, Chiche L, Daniel L, Lauwerys B, Weyenbergh JV, Jourde-Chiche N. Serum GlycA level is elevated in active systemic lupus erythematosus and correlates to disease activity and lupus nephritis severity. J Clin Med 2020; 9(4): 970.
[http://dx.doi.org/10.3390/jcm9040970] [PMID: 32244481]
[32]
Selvam AP, Wangzhou A, Jacobs M, Wu T, Mohan C, Prasad S. Development and validation of an impedance biosensor for point-of-care detection of vascular cell adhesion molecule-1 toward lupus diagnostics. Future Sci OA 2017; 3(3)FSO224
[http://dx.doi.org/10.4155/fsoa-2017-0047] [PMID: 28884017]
[33]
Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9(10): 899-909.
[http://dx.doi.org/10.1096/fasebj.9.10.7542214] [PMID: 7542214]